Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 270

1.

Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.

Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ.

Clin Cancer Res. 2019 Nov 11. doi: 10.1158/1078-0432.CCR-19-1920. [Epub ahead of print]

PMID:
31712383
2.

Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer.

Apolo AB, Milowsky MI, Kim L, Inman BA, Kamat AM, Steinberg G, Bagheri M, Krishnasamy VP, Marko J, Dinney CP, Bangs R, Sweis RF, Maher VE, Ibrahim A, Liu K, Werntz R, Cross F, Beaver JA, Singh H, Pazdur R, Blumenthal GM, Lerner SP, Bajorin DF, Rosenberg JE, Agrawal S.

JAMA Oncol. 2019 Oct 31:1-9. doi: 10.1001/jamaoncol.2019.4114. [Epub ahead of print]

PMID:
31670753
3.

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F; Bladder Cancer Molecular Taxonomy Group.

Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30695-5. doi: 10.1016/j.eururo.2019.09.006. [Epub ahead of print]

4.

Erratum to "Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder" [Eur Urol Focus 2018;4:907-915].

Piyarathna DWB, Rajendiran TM, Putluri V, Vantaku V, Soni T, von Rundstedt FC, Donepudi SR, Jin F, Maity S, Ambati CR, Dong J, Gödde D, Roth S, Störkel S, Degener S, Michailidis G, Lerner SP, Pennathur S, Lotan Y, Coarfa C, Sreekumar A, Putluri N.

Eur Urol Focus. 2019 Sep;5(5):920. doi: 10.1016/j.euf.2019.08.010. Epub 2019 Aug 30. No abstract available.

PMID:
31474581
5.

DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolism.

Vantaku V, Amara CS, Piyarathna DWB, Donepudi SR, Ambati CR, Putluri V, Tang W, Rajapakshe K, Estecio MR, Terris MK, Castro PD, Ittmann MM, Williams SB, Lerner SP, Sreekumar A, Bollag R, Coarfa C, Kornberg MD, Lotan Y, Ambs S, Putluri N.

Carcinogenesis. 2019 Nov 25;40(11):1332-1340. doi: 10.1093/carcin/bgz128.

PMID:
31284295
6.

Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.

Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, Bareja R, Park K, Tavassoli P, Cyrta J, Tagawa ST, Nanus DM, Beltran H, Molina AM, Khani F, Miguel Mosquera J, Xylinas E, Shariat SF, Scherr DS, Rubin MA, Lerner SP, Matin SF, Elemento O, Faltas BM.

Nat Commun. 2019 Jul 5;10(1):2977. doi: 10.1038/s41467-019-10873-y.

7.

Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors.

Lotan Y, Boorjian SA, Zhang J, Bivalacqua TJ, Porten SP, Wheeler T, Lerner SP, Hutchinson R, Francis F, Davicioni E, Svatek RS, Chen CL, Black PC, Gibb EA.

Eur Urol. 2019 Aug;76(2):200-206. doi: 10.1016/j.eururo.2019.04.036. Epub 2019 May 12.

PMID:
31092337
8.

The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability.

Kim J, Kwiatkowski D, McConkey DJ, Meeks JJ, Freeman SS, Bellmunt J, Getz G, Lerner SP.

Eur Urol. 2019 Jun;75(6):961-964. doi: 10.1016/j.eururo.2019.02.017. Epub 2019 Mar 7.

PMID:
30851984
9.

Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer.

Vantaku V, Dong J, Ambati CR, Perera D, Donepudi SR, Amara CS, Putluri V, Ravi SS, Robertson MJ, Piyarathna DWB, Villanueva M, von Rundstedt FC, Karanam B, Ballester LY, Terris MK, Bollag RJ, Lerner SP, Apolo AB, Villanueva H, Lee M, Sikora AG, Lotan Y, Sreekumar A, Coarfa C, Putluri N.

Clin Cancer Res. 2019 Jun 15;25(12):3689-3701. doi: 10.1158/1078-0432.CCR-18-1515. Epub 2019 Mar 7.

PMID:
30846479
10.

Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature.

Foerster B, D'Andrea D, Abufaraj M, Broenimann S, Karakiewicz PI, Rouprêt M, Gontero P, Lerner SP, Shariat SF, Soria F.

Urol Oncol. 2019 Jul;37(7):430-436. doi: 10.1016/j.urolonc.2019.02.004. Epub 2019 Mar 4. Review.

PMID:
30846387
11.

Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts.

Sikic D, Wirtz RM, Wach S, Dyrskjøt L, Erben P, Bolenz C, Breyer J, Otto W, Hoadley KA, Lerner SP, Eckstein M, Hartmann A, Keck B.

Transl Oncol. 2019 Apr;12(4):661-668. doi: 10.1016/j.tranon.2019.01.005. Epub 2019 Mar 2.

12.

What is the Standard of Care for Pelvic Lymphadenectomy Performed at the Time of Radical Cystectomy?

Lerner SP, Svatek RS.

Eur Urol. 2019 Apr;75(4):612-614. doi: 10.1016/j.eururo.2018.12.028. Epub 2019 Jan 4. No abstract available.

PMID:
30616946
13.

SIU-ICUD consultation on bladder cancer: basic science.

McConkey DJ, Lerner SP.

World J Urol. 2019 Jan;37(1):15-29. doi: 10.1007/s00345-018-2594-y. Epub 2018 Dec 13. Review.

PMID:
30547196
15.

The Cancer Genome Atlas Project in Bladder Cancer.

Rodriguez-Vida A, Lerner SP, Bellmunt J.

Cancer Treat Res. 2018;175:259-271. doi: 10.1007/978-3-319-93339-9_12.

PMID:
30168126
16.

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network, Weinstein JN, Kwiatkowski DJ, Lerner SP.

Cell. 2018 Aug 9;174(4):1033. doi: 10.1016/j.cell.2018.07.036. No abstract available.

17.

Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.

Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP Jr, Mack PC, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, Wu G, Plets M, Vogelzang NJ, Thompson IM Jr.

JAMA. 2018 May 8;319(18):1880-1888. doi: 10.1001/jama.2018.4657.

18.

Prognostication in Patients Treated with Radical Cystectomy for Urothelial Bladder Carcinoma: A New Simplified Model Incorporating Histological Variants.

Ku JH, Yuk HD, Godoy G, Amiel GE, Lerner SP.

Bladder Cancer. 2018 Apr 26;4(2):195-203. doi: 10.3233/BLC-170156.

19.

Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study.

Tu H, Dinney CP, Ye Y, Grossman HB, Lerner SP, Wu X.

Am J Clin Nutr. 2018 Feb 1;107(2):208-216. doi: 10.1093/ajcn/nqx019.

20.

Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis.

Westhoff E, Witjes JA, Fleshner NE, Lerner SP, Shariat SF, Steineck G, Kampman E, Kiemeney LA, Vrieling A.

Bladder Cancer. 2018 Jan 20;4(1):91-112. doi: 10.3233/BLC-170147.

21.

Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer.

Westhoff E, Wu X, Kiemeney LA, Lerner SP, Ye Y, Huang M, Dinney CP, Vrieling A, Tu H.

Int J Cancer. 2018 May 1;142(9):1797-1804. doi: 10.1002/ijc.31214. Epub 2017 Dec 26.

22.

Molecular Landscape of Non-Muscle Invasive Bladder Cancer.

Meeks JJ, Lerner SP.

Cancer Cell. 2017 Nov 13;32(5):550-551. doi: 10.1016/j.ccell.2017.08.015.

23.

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network, Weinstein JN, Kwiatkowski DJ, Lerner SP.

Cell. 2017 Oct 19;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007. Epub 2017 Oct 5. Erratum in: Cell. 2018 Aug 9;174(4):1033.

24.

Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer.

Jin F, Thaiparambil J, Donepudi SR, Vantaku V, Piyarathna DWB, Maity S, Krishnapuram R, Putluri V, Gu F, Purwaha P, Bhowmik SK, Ambati CR, von Rundstedt FC, Roghmann F, Berg S, Noldus J, Rajapakshe K, Gödde D, Roth S, Störkel S, Degener S, Michailidis G, Kaipparettu BA, Karanam B, Terris MK, Kavuri SM, Lerner SP, Kheradmand F, Coarfa C, Sreekumar A, Lotan Y, El-Zein R, Putluri N.

Cancer Prev Res (Phila). 2017 Oct;10(10):588-597. doi: 10.1158/1940-6207.CAPR-17-0198. Epub 2017 Aug 29.

25.

Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.

Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN.

J Clin Oncol. 2017 Oct 20;35(30):3410-3416. doi: 10.1200/JCO.2017.72.3064. Epub 2017 Aug 23. Erratum in: J Clin Oncol. 2019 Aug 20;37(24):2187.

26.

Editorial Concerning "Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy".

Shen S, Lerner SP.

Bladder Cancer. 2017 Jul 27;3(3):171-172. doi: 10.3233/BLC-179017. No abstract available.

27.

New Sister Journal Kidney Cancer.

Lerner SP, Theodorescu D.

Bladder Cancer. 2017 Jul 27;3(3):143. doi: 10.3233/BLC-179021. No abstract available.

28.

Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary.

Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM.

J Oncol Pract. 2017 Sep;13(9):621-625. doi: 10.1200/JOP.2017.024919. Epub 2017 Aug 10. No abstract available.

PMID:
28796558
29.

Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder.

Piyarathna DWB, Rajendiran TM, Putluri V, Vantaku V, Soni T, von Rundstedt FC, Donepudi SR, Jin F, Maity S, Ambati CR, Dong J, Gödde D, Roth S, Störkel S, Degener S, Michailidis G, Lerner SP, Pennathur S, Lotan Y, Coarfa C, Sreekumar A, Putluri N.

Eur Urol Focus. 2018 Dec;4(6):907-915. doi: 10.1016/j.euf.2017.04.005. Epub 2017 Apr 20. Erratum in: Eur Urol Focus. 2019 Sep;5(5):920.

30.

Prognostic Significance of Neutrophilic Infiltration in Benign Lymph Nodes in Patients with Muscle-invasive Bladder Cancer.

Pal SK, Pham A, Vuong W, Liu X, Lin Y, Ruel N, Yuh BE, Chan K, Wilson T, Lerner SP, McConkey D, Jove R, Liang W.

Eur Urol Focus. 2017 Feb;3(1):130-135. doi: 10.1016/j.euf.2016.03.003. Epub 2016 Mar 25.

PMID:
28720358
31.

Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.

Moss TJ, Qi Y, Xi L, Peng B, Kim TB, Ezzedine NE, Mosqueda ME, Guo CC, Czerniak BA, Ittmann M, Wheeler DA, Lerner SP, Matin SF.

Eur Urol. 2017 Oct;72(4):641-649. doi: 10.1016/j.eururo.2017.05.048. Epub 2017 Jun 7.

PMID:
28601352
32.

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.

Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM.

J Urol. 2017 Sep;198(3):552-559. doi: 10.1016/j.juro.2017.04.086. Epub 2017 Apr 26. Erratum in: J Urol. 2017 Nov;198(5):1175.

33.

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC.

Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5.

PMID:
28390739
34.

Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.

Choi W, Ochoa A, McConkey DJ, Aine M, Höglund M, Kim WY, Real FX, Kiltie AE, Milsom I, Dyrskjøt L, Lerner SP.

Eur Urol. 2017 Sep;72(3):354-365. doi: 10.1016/j.eururo.2017.03.010. Epub 2017 Mar 30. Review.

35.

Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study.

von Rundstedt FC, Mata DA, Kryvenko ON, Shah AA, Jhun I, Lerner SP.

Bladder Cancer. 2017 Jan 27;3(1):35-44. doi: 10.3233/BLC-160062.

36.

Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior.

Mobley A, Zhang S, Bondaruk J, Wang Y, Majewski T, Caraway NP, Huang L, Shoshan E, Velazquez-Torres G, Nitti G, Lee S, Lee JG, Fuentes-Mattei E, Willis D, Zhang L, Guo CC, Yao H, Baggerly K, Lotan Y, Lerner SP, Dinney C, McConkey D, Bar-Eli M, Czerniak B.

Sci Rep. 2017 Jan 19;7:40714. doi: 10.1038/srep40714.

37.

Bacillus Calmette-Guérin Manufacturing and SWOG S1602 Intergroup Clinical Trial.

Meeks JJ, Lerner SP, Svatek RS.

J Urol. 2017 Mar;197(3 Pt 1):538-540. doi: 10.1016/j.juro.2016.12.024. Epub 2016 Dec 16. No abstract available.

PMID:
27992750
38.

Transurethral biopsy of the prostatic urethra is associated with final apical margin status at radical cystoprostatectomy.

von Rundstedt FC, Mata DA, Shen S, Li Y, Godoy G, Lerner SP.

J Clin Urol. 2016 Nov;9(6):404-408. Epub 2016 Nov 2.

39.

Diagnostic and Prognostic Markers in Bladder Cancer.

Ku JH, Kim WJ, Lerner SP, Chun F, Kluth LA.

Dis Markers. 2016;2016:2425091. Epub 2016 Sep 29. No abstract available.

40.

Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710.

Ojerholm E, Smith A, Hwang WT, Baumann BC, Tucker KN, Lerner SP, Mamtani R, Boursi B, Christodouleas JP.

Cancer. 2017 Mar 1;123(5):794-801. doi: 10.1002/cncr.30422. Epub 2016 Oct 27.

41.

Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC).

Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, Spiess PE, Lotan Y, Ye D, Fernández MI, Kikuchi E, Chade DC, Babjuk M, Grollman AP, Thalmann GN.

World J Urol. 2017 Mar;35(3):379-387. doi: 10.1007/s00345-016-1928-x. Epub 2016 Sep 7. Review.

PMID:
27604375
42.

The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.

Barbieri CE, Chinnaiyan AM, Lerner SP, Swanton C, Rubin MA.

Eur Urol. 2017 Feb;71(2):237-246. doi: 10.1016/j.eururo.2016.08.024. Epub 2016 Aug 25. Review.

43.

Molecular Subtypes of Non-muscle Invasive Bladder Cancer.

Lerner SP, Robertson AG.

Cancer Cell. 2016 Jul 11;30(1):1-3. doi: 10.1016/j.ccell.2016.06.012.

44.

Bladder cancer: ASCO endorses EAU muscle-invasive bladder cancer guidelines.

Lerner SP.

Nat Rev Urol. 2016 Aug;13(8):440-1. doi: 10.1038/nrurol.2016.114. Epub 2016 Jul 5. Review. No abstract available.

PMID:
27377160
45.

Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.

Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ.

Bladder Cancer. 2016 Apr 27;2(2):165-202.

46.

Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting.

Lerner SP, McConkey DJ, Hoadley KA, Chan KS, Kim WY, Radvanyi F, Höglund M, Real FX.

Bladder Cancer. 2016 Jan 7;2(1):37-47.

47.

Bladder cancer.

Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y, Kassouf W.

Lancet. 2016 Dec 3;388(10061):2796-2810. doi: 10.1016/S0140-6736(16)30512-8. Epub 2016 Jun 23. Review. Erratum in: Lancet. 2016 Dec 3;388(10061):2742.

PMID:
27345655
48.

Validating a Local Failure Risk Stratification for Use in Prospective Studies of Adjuvant Radiation Therapy for Bladder Cancer.

Baumann BC, He J, Hwang WT, Tucker KN, Bekelman JE, Herr HW, Lerner SP, Guzzo TJ, Malkowicz SB, Christodouleas JP.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):703-6. doi: 10.1016/j.ijrobp.2016.01.034. Epub 2016 Jan 23.

49.

The case for salvage cystectomy after pelvic radiation.

Calderone CE, Lerner SP, Taylor JM.

Minerva Urol Nefrol. 2016 Apr;68(2):161-71. Epub 2016 Mar 16. Review.

50.

Bacille-Calmette-Guerin non-responders: how to manage.

von Rundstedt FC, Lerner SP.

Transl Androl Urol. 2015 Jun;4(3):244-53. doi: 10.3978/j.issn.2223-4683.2015.05.03. Review.

Supplemental Content

Loading ...
Support Center